Kornimate/medical-research-clean huggingface dataset:
evaluation of the prevalence and risk factors for patients with peri-implant disease：a retrospective study

Conditions: Jaw, Edentulous, Partially

Summary: to investigate the patient-related risk factors for peri-implant disease in partially edentulous patients rehabilitated with implants supported crown or bridge so as to provide evidence for clinical prevention and control.

objective: to investigate the patient-related risk factors for peri-implant disease in partially edentulous patients rehabilitated with implants supported crown or bridge so as to provide evidence for clinical prevention and control. methods:a total of 131 patients will enroll in the study. univariate and multivariate logistic regression analysis is used to determine the patient factors associated with peri-implant disease. the variables include age, gender, smoking and alcohol consumption, presence of diabetes, cardiovascular disease, osteoporosis, bruxism, bleeding upon brushing, reason for extraction, oral hygiene and periodontal status.

Eligibility criteria:
inclusion criteria: patients implanted at least one implant and restored with implant-supported fixed partial dentures and single crowns. the implant-supported fixed partial dentures and single crowns were in function at least one year. exclusion criteria: jaw radiotherapy treatment before and after implanting. patients who have bruxism, xerostomia or the adjacent teeth periapical periodontitis. patients who suffered with oral mucosa disease,or aggressive periodontitis or jaw defect. patients who suffered with mental and psychological disease will influence their oral health normal maintenance.

Keywords: peri-implant disease; risk factors; prevalence
endostatin in combination with oxaliplatin and radiotherapy in esophageal cancer patients.

Conditions: Esophageal Cancer; Endostatin

Summary: endostatin inhibits the pro-angiogenic action of basic fibroblast growth factor and vascular endothelial growth factor in esophageal cancer.this study aims at assessing the efficacy and safety of endostatin combined with concurrent chemoradiotherapy with oxaliplatin in esophageal cancer patients.


Eligibility criteria:
inclusion criteria: 1. cytologically or histologically confirmed esophageal carcinoma 2. age of 18 -80 3. ecog performance status: 0-1; 4. no treatments prior to enrollment; 5. at least one measurable lesion on ct, mri or esophageal barium exam; 6. normal functions of heart, lung, liver, kidney and bone marrow blood exams qualified for chemotherapy, which included hemoglobulin ≥9 g/dl, neutrophil ≥1.5×109/l and platelet (plt) ≥100×109/l, creatinine ≤1.5 unl 7. informed consent signed exclusion criteria: 1. prior treatments of chemotherapy or irradiation; 2. poor bone marrow, liver and kidney functions, which would make chemotherapy intolerable; 3. contraindication for irradiation: complete obstruction of esophagus, deep esophageal ulcer, fistula to mediastinum, or haematemesis; 4. participating in other clinical trials; 5. pregnancy, breast feeding, or not adopting birth control; 6. clinically significant and uncontrolled major medical conditions including but not limited to: active uncontrolled infection, symptomatic congestive heart failure, unstable angina pectoris or cardiac arrhythmia, psychiatric illness/ social situation that would limit compliance with study requirements; any medical condition, which in the opinion of the study investigator places the subject at an unacceptably high risk for toxicities 7. the subject has had another active malignancy within the past five years except for cervical cancer in site, in situ carcinoma of the bladder or non-melanoma carcinoma of the skin;

Keywords: endostatin oxaliplatin esophageal cancer chemoradiotherapy
phase 1 study of mkc-1 in patients with advanced cancer

Conditions: Advanced Cancer

Summary: this is an open-label study to determine the highest dose of mkc-1 that may be administered daily on a continuous basis for patients with advanced or refractory solid tumors.


Eligibility criteria:
inclusion criteria: * have histologically confirmed malignancy that is metastatic or unresectable and for which standard curative measures do not exist or are no longer effective. * age greater than or equal to 18 years. * ecog performance status ≤1 * anc greater than or equal to 1,500/mm3; * platelets greater than or equal to 100,000/mm3 * creatinine ≤1.5 times institutional upper limit of normal (uln) * t bili within normal limits; * ast and alt less than or equal to 2.5 times uln; and * albumin greater than or equal to 3.0 g/dl * have measurable disease by recist, radiographically evaluable disease, or detectable disease * women of child-bearing potential and men must agree to use adequate contraception * ability to understand and the willingness to sign a written informed consent document. exclusion criteria: * have previously received mkc-1. * have received radiation to greater than 25% of the bone marrow. * have had anti-cancer therapy within 4 weeks prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier. * are concurrently receiving any other investigational agents while on study. * have known brain metastases * have any condition that impairs the ability to swallow and retain mkc-1 capsules. * uncontrolled intercurrent illness * are pregnant or breastfeeding * hiv-positive patients * patients with uncontrolled diabetes

Keywords: advanced cancer
a trial evaluating the effects of zoledronic acid 5 mg infusion on bone mineral density (bmd) in postmenopausal osteoporosis (pmo) patients between the ages of 50 and 65 years

Conditions: Postmenopausal Osteoporosis

Summary: this study will evaluate the effects of zoledronic acid 5 mg infusion on bmd and biochemical markers of bone in post-menopausal osteoporotic patients aged between 50-65.


Eligibility criteria:
inclusion criteria: * postmenopausal osteoporosis * patients who has a low bone mineral density at hip or vertebral * patients who has an osteoporotic fracture at hip or vertebra exclusion criteria: * hypersensitivity either to the active substance or to any of the excipients or to any biphosphonates. * known metabolic bone disease excluding osteoporosis. * serious systemic disorder treated with drugs interfering with bone metabolism. * significant liver or renal failure * pathologic fracture in the examined body area or elsewhere. * previous anti-osteoporotic treatment within 12 months or less prior to the recruitment. * patients with hypocalcaemia other protocol-defined inclusion/exclusion criteria may apply

Keywords: osteoporosis bone mineral density biomarkers
metformin in children with motor deficit

Conditions: Spina Bifida; Neuromuscular Diseases

Summary: obesity with insulin resistance in the paediatric population provides an increasing challenge. children with neurological or neuromuscular diseases are even more prone to obesity: their locomotor impairment leads to an increasingly sedentary lifestyle, a decrease in physical fitness and an increase in body fat (1-3). obesity, in turn, can be associated with a decrease in physical fitness and a further increase in body fat. in this study we want to evaluate the effect of an insulin-sensitizer, metformin, in a group of overweight/obese patients with neurological or neuromuscular diseases. metformin is a well-established insulin sensitizer.

obesity with insulin resistance in the paediatric population provides an increasing challenge. children with neurological or neuromuscular diseases are even more prone to obesity: their locomotor impairment leads to an increasingly sedentary lifestyle, a decrease in physical fitness and an increase in body fat (1-3). obesity, in turn, can be associated with a decrease in physical fitness and a further increase in body fat. in this study we want to evaluate the effect of an insulin-sensitizer, metformin, in a group of overweight/obese patients with neurological or neuromuscular diseases. metformin is a well-established insulin sensitizer.

Eligibility criteria:
inclusion criteria: * patients with neurogenic or myogenic motor deficit, clinically obese or who had excessively gained weight over the last year. exclusion criteria: * exclusion criteria were known type 1 or type 2 diabetes mellitus and contraindications to metformin therapy.

Keywords: metformin, spina bifida, duchenne, insulin resistance
immunogenicity and safety of an adjuvanted hbv vaccine compared to engerix™-b, in a non-responder population ≥ 15y

Conditions: Hepatitis B

Summary: subjects who had not responded to previous hepatitis b vaccination were vaccinated with either the adjuvanted hbv-mpl vaccine or engerix™-b vaccine according to a three-dose vaccination schedule (0, 1, 2 months) and boosted at month 12 as per their group allocation. the immunogenicity and safety of the hbv-mpl vaccine were compared with the control vaccine, engerix™-b.

at the time of conduct of this study, the sponsor glaxosmithkline was known by its former name smithkline beecham.

Eligibility criteria:
inclusion criteria: at study entry: * a male or female ≥ 15 years of age at the time of the first vaccination. * free of obvious health problems as established by medical history and clinical examination before entering into the study. * written informed consent obtained from the subject. * documented non-response to previous hepatitis b vaccination within 6 months after having received a full vaccination course (i.e. ≥ 3 doses of a hepatitis b vaccine) * if the subject is female, she must be of non-childbearing potential, or, if of childbearing potential, she must be abstinent or use adequate contraceptive precautions for one month prior to enrollment and up to two months after the last vaccination. before booster dose at month 12: * additional written informed consent covering the booster administration and blood samples at months 12 and 13 must be obtained from the subject. * if the subject is female, she must be of non-childbearing potential, or, if of childbearing potential, she must be abstinent or use adequate contraceptive precautions for one month prior to and up to two months after the administration of the booster dose exclusion criteria: * use of any investigational or non-registered drug or vaccine other than the study vaccine(s) during the study period or within 30 days preceding the first dose of study vaccine. * planned administration/ administration of a vaccine not foreseen by the study protocol during the period starting from 30 days before each dose of vaccine and ending 30 days after. * known exposure to hepatitis b within 6 weeks. * history of hepatitis b infection. * confirmed human immunodeficiency virus (hiv) infection. * a family history of congenital or hereditary immunodeficiency. * history of allergic disease/reactions likely to be exacerbated by any component of the vaccine. * acute disease at the time of enrollment. * hepatomegaly, right upper quadrant abdominal pain or tenderness. * administration of immunoglobulins and/or any blood products within the three months preceding the first dose of study vaccine or planned administration/ administration during the study period. * pregnant or lactating female.

Keywords: hepatitis b adjuvanted vaccine
the sim-sof trial for hepatitis c

Conditions: Chronic Hepatitis C

Summary: randomized trial of hepatitis c-genotype 1-infected patients with compensated cirrhosis comparing the standard of care (peginterferon/ribavirin/sofosbuvir) versus the off-label combination of simeprevir+ sofosbuvir without ribavirin.

patients can be treatment naive or prior null response to peg/rbv, and must be genotype subtype 1a. must have child's class a cirrhosis/compensated and no history of decompensation

Eligibility criteria:
inclusion criteria: * chronic hepatitis c, * cirrhosis biopsy-proven, or via fibrotest, * cpt score less than 7, * genotype 1a, * inr 2.3 or less, * serum albumin greater than 2.7 gm/dl, * total bilirubin less than 3 gm/dl, * platelet count 50,000 per cubic milliliter or more * gfr \>50 ml/min exclusion criteria: * non genotype 1a, * history of cpt class b or c or decompensation or history of same, * hiv or hbv coinfection, * prior treatment with boceprevir, telaprevir or any other direct acting antiviral agent, * uncontrolled psychiatric or cardiopulmonary disorders, * planning pregnancy or unwilling/unable to practice contraception

Keywords: cirrhosis
comparison of intravenous lidocaine vs ketamine in colorectal surgery

Conditions: Colorectal (Colon or Rectal) Cancer; Inflammation

Summary: patients undergoing open colorectal surgery were randomly divided into two groups: intravenous lidocaine (iv-lido) vs intravenous ketamine (iv-keta). for the iv-lido group, patients received a loading dose of lidocaine than a continuous infusion over twenty-four hours. for the iv-keta goup, patients received a loading dose of ketamine than a continuous injection of ketamine over twenty-four hours. plasma concentrations of interleukin-6(il-6) were measured preoperatively before anesthetic induction and at twenty-four hour post operatively.

patients undergoing open colorectal surgery with tumor resection were randomised prospectively into two groups: intravenous lidocaine (iv-lido) vs intravenous ketamine (iv-keta). for the iv-lido group (n=25), patients received a loading dose of 1.5 mg/kg of lidocaine than a continuous infusion of 1.5 mg/kg/h over twenty-four hours. for the iv-keta goup(n=25), patients received a loading dose of 0.15mg/kg of ketamine than a continuous injection of 0.15 mg/kg/h of ketamine over twenty-four hours. for both groups, plasma concentrations of interleukin-6(il-6) were measured preoperatively before anesthetic induction and at twenty-four hour post operatively. plasma il-6 concentrations at each point were compared between the groups.

Eligibility criteria:
inclusion criteria: * patients aged 18 or older. * american society of anesthesiologists' (asa) physical status of i-iii. * elective open colorectal surgery. non inclusion criteria: * patients with contraindications to lidocaine or ketamine. * corticosteroid therapy within the last 6 months. * history of immunosuppressive therapy. * history of surgery in the last 3 months. * personal medical history of inflammatory bowel disease. * personal medical history of cardiac arrythmias or conduction disorders. * alcohol or drug abuse. * chronic use of opioids or benzodiazepines. exclusion criteria: * severe intraoperative complications. * duration of surgery longer than 5 hours.
effect of abdominal obesity on lipoprotein metabolism

Conditions: Obesity; Dyslipidemia; Insulin Resistance

Summary: abdominal obesity is strongly associated with dyslipidemia, which may account for the associated increased risk of atherosclerosis and coronary disease. weight reduction is suggested to be a preferred and effective first-line strategy to correct lipid abnormalities, particularly in overweight/obese subjects. this improvement may be related to the effect of reduction in abdominal fat mass on apob and apoa-i metabolism, but this remains to be fully demonstrated. hypothesis: reduction in abdominal fat mass by weight loss decreases apob concentration and raises hdl-cholesterol chiefly by increasing ldl-apob fractional catabolic rate (fcr), as well as decreasing hdl apoa-i, respectively.

we examined the mechanism of the effect of weight loss through dieting on ldl and hdl metabolism in abdominally obese men. ldl apob-100 and hdl apoa-i kinetics were studied using a primed-constant infusion of 1-\[13c\]-leucine in a controlled, dietary intervention trial of 16 weeks duration in middle-aged, obese men with the metabolic syndrome. isotopic enrichment in apob and apoa-i was measured by gas chromatography-mass spectrometry and fractional turnover rates estimated using multi-compartmental modelling.

Eligibility criteria:
inclusion criteria: * obesity was defined as a body mass index (bmi) \>28kg/m2 and visceral visceral obesity (waist to hip ratio\> 1.0 or waist circumference \>100 cm) exclusion criteria: * diabetes mellitus, * proteinuria, * hypothyroidism, * abnormal liver enzymes, * major systemic illness, * a history of alcohol abuse, * a family history of hyperlipidemia or premature coronary artery disease or were taking medication known to affect lipid metabolism.

Keywords: lipoprotein metabolism cardiovascular disease obesity
gene expression in tissue from patients with acute lymphoblastic leukemia

Conditions: Leukemia

Summary: rationale: studying the genes expressed in samples of tumor tissue from patients with cancer may help doctors identify biomarkers related to cancer. purpose: this laboratory study is looking at gene expression in tissue from patients with acute lymphoblastic leukemia enrolled in clinical trial ecog-2993.

objectives: * identify genes involved in specific biologic processes or molecular functions that contribute to the mechanisms by which the bcr/abl tyrosine kinase induces a leukemic phenotype using rna banked from patients with bcr/abl-positive acute lymphoblastic leukemia (all) enrolled on ecog-2993. * compare patterns of mrna expression of bcr/abl fusion protein in patients with b-lineage all vs patients with all and no cytogenetic abnormalities enrolled on ecog-2993. * determine both shared and differing expression patterns in patients with bcr/abl-positive and cytogenetically negative all with respect to achievement of complete remission and duration of disease-free and overall survival. outline: this is a multicenter study. total rna is isolated from stored tissue samples and integrity is verified by reverse transcription-polymerase chain reaction (rt-pcr). cdna libraries are created from total rna and gene expression is analyzed via microarray analysis. genes of interest are further analyzed by flow cytometry and rt-pcr. projected accrual: a total of 137 patients will be accrued for this study.

Eligibility criteria:
disease characteristics: * confirmed diagnosis of acute lymphoblastic leukemia * tissue banked on protocol ecog-2993 meeting the following criteria: * leukemic blast cell population immunophenotyped in detail (e.g., including cd25) in ecog's immunophenotyping reference laboratory * flow cytometric analysis of gated blast cells reveals association with the b-cell lineage * mononuclear cell fraction used for rna isolation contains 75-99% blasts (median 85%) * negative for tel/aml1, mll/af4, and e2a/pbx1 by qualitative reverse transcription-polymerase chain reaction (rt-pcr) * no flt3 gene mutations * bcr/abl-positive samples meeting the following criteria: * presence of t(9;22)(q34;q11) by standard cytogenetics * detection of either p190 bcr/abl or p210 bcr/abl transcripts by qualitative rt-pcr * patients with genetic risk factors must meet the following criterion: * only a normal diploid karyotype is present in ≥ 15 metaphases by standard cytogenetics patient characteristics: * not specified prior concurrent therapy: * not specified

Keywords: adult acute lymphoblastic leukemia in remission
anterior segment changes after pars plana vitrectomy with so using as-oct

Conditions: Glaucoma

Summary: to evaluate changes in aca induced by pars plana vitrectomy with so 1000cs injection in vitreo-retinal surgery in phakic eyes using as-oct and changes in the iop preoperatively, post-operatively and post-silicone oil evacuation.

abstract introduction ocular hypertension and secondary glaucoma are relatively common and serious complications in silicone filled eyes which may end in blindness. reports have described the percentage of incidence to be within 3 - 30 % of silicon filled eye which are complicated with secondary glaucoma. \[1\] aim of study evaluation of changes in anterior chamber angle and intra-ocular pressure (iop) in patients with rhegmatogenous retinal detachment (rrd) who underwent pars plana vitrectomy (ppv) with silicone oil (so) 1000cs tamponade and after silicone oil evacuation. population the study was a prospective interventional study. the study included 30 eyes from 30 patients with rhegmatogenous retinal detachment (rrd) who are going to undergo ppv with so injection. the study was conducted at ophthalmology department, minia university hospital in egypt between april 2023 and april 2024.

Eligibility criteria:
inclusion criteria: * • patients with rhegmatogenous retinal detachment who are going to undergo vitreoretinal surgery with silicone oil 1000cs injection as tamponade exclusion criteria: * patients with history of intraocular surgery, laser therapy or intravitreal injection. * patients with significant corneal opacity. * patients with ocular diseases as retinal vein occlusion, uveitis and proliferative diabetic retinopathy. * patients with preexisting glaucoma or family history of glaucoma. * patients with nystagmus. * patient with tractional retinal detachment, exudative retinal detachment or intraocular foreign body. * patients with anterior chamber abnormalities including posterior synechia, peripheral anterior synechia, hyphaema and iris abnormalities. * patients with severe proliferative vitreoretinopathy grade c or more.

Keywords: asoct glaucoma silicone vitrectomy angle
toothpastes with thermal water for oral health

Conditions: Gingivitis; Dentin Hypersensitivity

Summary: the aim of the study is to compare the effect of toothpastes containing thermal water of castera-verduzan with 1450 ppm fluoride and without fluorinated derivatives on oral hygiene, gingivitis, and dentin hypersensitivity in young adults.

this will be a double-blind, randomized, two-arm parallel-group study of the effect of toothpastes containing thermal water of castera-verduzan with 1450 ppm fluoride and without fluorinated derivatives. the groups will include adults with gingivitis and dentinal hypersensitivity (dh) diagnosed clinically. to assess the effect of the toothpastes, the following parameters will be used: gingival health (modified gingival index, mgi; gingival bleeding index, bi), dentin sensitivity (shiff's index, vas), oral hygiene level (navi-rustogi index), and salivary ph.

Eligibility criteria:
inclusion criteria: * aged between 20-25 years * signed an approved informed consent form, authorizing the participation in the trial and the use of the results of the trial for educational purposes and for the publication * the diagnosis of gingivitis stated clinically * at least one tooth with the diagnosis of dentin hypersensitivity stated clinically exclusion criteria: * medical and pharmacotherapeutic histories that may compromise the protocol (pregnancy or breastfeeding, psychiatric disorders, allergies to toothpastes ingredients, eating disorders) * systemic conditions that are etiologic to dentin hypersensitivity (e.g., chronic acid regurgitation) history of chemotherapy or radiotherapy * taking antibiotic, anti-inflammatory, or anti-coagulant medications 4 weeks prior to or after the baseline visit * oral mucosa pathology * periodontal surgery in the preceding 3 months * orthodontic appliance treatment within previous 3 months * teeth or supporting structures with any other painful pathology or defects * taking any other agents for dh management 4 weeks prior to or after the baseline visit * extensively restored teeth and those with restorations extending into the cervical area * dental bleaching within previous 3 months * subject withdrawal of consent * subject is not compliant with study procedures * adverse event that in the opinion of the investigator would be in the best interest of the subject to discontinue study participation

Keywords: gingivitis dentin sensitivity thermal water toothpaste fluoride